Alnylam’s Blood Pressure Drug: Not Exactly Heartwarming Yet
Alnylam just dropped data from their so-called 'investigational therapy' that was supposed to be the Tesla of blood pressure meds but ended up more like a tricycle. Their Phase 2 trial, aka the 'Thrill of Mediocrity,' didn't significantly lower blood pressure. Yet, in a plot twist worthy of a soap opera reboot, the company decided to plunge forward into a late-stage study—because why quit when you can pretend progress? No dollar amounts or dates were shared, but one thing’s clear: Alnylam is writing a new chapter in the 'Lower Your Expectations' saga. If clinical trials were auditions, this one got a polite nod to keep trying.
Share the Story
(1 of 3)Alnylam’s blood pressure med didn’t budge the dial, but hey, let’s double down on hope and move to late stage—because who doesn’t love trying the same thing harder until it magically works?
Who knew the secret to clinical success is a solid game of pretend? Alnylam’s drug flopped Phase 2 yet gets a free pass to late stage like it’s the kid who flunked math but still makes varsity cheerleading.
'Significantly lowers blood pressure' took a sick day, but Alnylam’s optimism shows up on time and boots—time to double down on science’s version of 'hold my beer.'
Source: Statnews | Published: 8/30/2025 | Author: Elaine Chen
More Articles in Health
Microsoft Finally Lets Windows 11 Fans Stop Pretending to Use ViVeTool
Epstein Survivors Declare 'Done' While Melania Passes the Buck Faster Than a Baton
VP Vance Heads to Pakistan to Broker Peace, Backed by Kushner and Trump’s Threats
Competitive Swimmer Drops 60 Pounds Using Costco Snacks, No Sweat Required
Telehealth Startup Outsources Doctors to AI and Angolan Phone Lines
Widow Turns Frozen Sperm Time Capsule Into Baby After 10-Year Hiatus
OpenAI CEO Temporarily Downgrades from AI Overlord to Human POTS Patient
Woman Quits Job at 38 to Audit Diaper Changing as Full-Time Gig
